Naproxen Sodium Patent Expiration
Naproxen Sodium was first introduced by Atnahs Pharma Us Ltd
Naproxen Sodium Patents
Given below is the list of patents protecting Naproxen Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Naproxen Sodium | US10022344 | Liquid dosage forms of sodium naproxen | Mar 03, 2026 | Bionpharma |
| Naproxen Sodium | US10028925 | Liquid dosage forms of sodium naproxen | Mar 03, 2026 | Bionpharma |
| Naproxen Sodium | US11090280 | Liquid dosage forms of sodium naproxen | Mar 03, 2026 | Bionpharma |
| Naproxen Sodium | US9693978 | Solvent system for enhancing the solubility of pharmaceutical agents | Mar 03, 2026 | Bionpharma |
| Naproxen Sodium | US9693979 | Liquid dosage forms of sodium naproxen | Mar 03, 2026 | Bionpharma |
| Naprelan | US5637320 | Controlled absorption naproxen formulation for once-daily administration |
Jun 10, 2014
(Expired) | Twi Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Naproxen Sodium's patents.
Latest Legal Activities on Naproxen Sodium's Patents
Given below is the list recent legal activities going on the following patents of Naproxen Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Jan, 2022 | US10028925 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jan, 2022 | US10022344 |
| Patent Issue Date Used in PTA Calculation Critical
| 17 Aug, 2021 | US11090280 |
| Recordation of Patent Grant Mailed Critical
| 17 Aug, 2021 | US11090280 |
| Email Notification Critical
| 29 Jul, 2021 | US11090280 |
| Issue Notification Mailed Critical
| 28 Jul, 2021 | US11090280 |
| Application Is Considered Ready for Issue Critical
| 22 Jul, 2021 | US11090280 |
| Dispatch to FDC | 22 Jul, 2021 | US11090280 |
| Response to Reasons for Allowance | 13 Jul, 2021 | US11090280 |
| Issue Fee Payment Verified Critical
| 13 Jul, 2021 | US11090280 |
Naproxen Sodium's Family Patents
